Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDJLY9)

Drug Name

NM-702 Drug Info

Synonyms

NM-702; Parogrelil hydrochloride; UNII-65O9DMS368; 65O9DMS368; NM702; NM 702; 878796-94-2; SCHEMBL1739368; QWGUGDYWUADMGB-UHFFFAOYSA-N; 3(2H)-Pyridazinone, 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-((3-pyridinylmethyl)amino)-, hydrochloride (1:1); 139145-84-9; 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Phase 3	[1]

Cross-matching ID

PubChem CID: 9848253
CAS Number: CAS 878796-94-2
TTD Drug ID: DMDJLY9

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase (PDE)	TTUST1O	NOUNIPROTAC	Inhibitor	[2]
Thromboxane-A synthase (TBXAS1)	TTKNWZ4	THAS_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Thromboxane-A synthase (TBXAS1)	DTT	TBXAS1	5.289	4.615	4.413	3.585

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Angina pectoris

ICD Disease Classification

BA40

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Thromboxane-A synthase (TBXAS1)	DTT	TBXAS1	6.56E-01	0.02	0.08

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials. 2011; 12: 134.
2	The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.